Correlation Between Royal Bank and Oncolytics Biotech

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Royal Bank and Oncolytics Biotech at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Royal Bank and Oncolytics Biotech into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Royal Bank of and Oncolytics Biotech, you can compare the effects of market volatilities on Royal Bank and Oncolytics Biotech and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Royal Bank with a short position of Oncolytics Biotech. Check out your portfolio center. Please also check ongoing floating volatility patterns of Royal Bank and Oncolytics Biotech.

Diversification Opportunities for Royal Bank and Oncolytics Biotech

0.02
  Correlation Coefficient

Significant diversification

The 3 months correlation between Royal and Oncolytics is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Royal Bank of and Oncolytics Biotech in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Oncolytics Biotech and Royal Bank is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Royal Bank of are associated (or correlated) with Oncolytics Biotech. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Oncolytics Biotech has no effect on the direction of Royal Bank i.e., Royal Bank and Oncolytics Biotech go up and down completely randomly.

Pair Corralation between Royal Bank and Oncolytics Biotech

Assuming the 90 days trading horizon Royal Bank of is expected to generate 0.11 times more return on investment than Oncolytics Biotech. However, Royal Bank of is 9.51 times less risky than Oncolytics Biotech. It trades about 0.07 of its potential returns per unit of risk. Oncolytics Biotech is currently generating about -0.08 per unit of risk. If you would invest  2,450  in Royal Bank of on December 4, 2024 and sell it today you would earn a total of  11.00  from holding Royal Bank of or generate 0.45% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

Royal Bank of  vs.  Oncolytics Biotech

 Performance 
       Timeline  
Royal Bank 

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Royal Bank of are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively stable basic indicators, Royal Bank is not utilizing all of its potentials. The recent stock price uproar, may contribute to short-horizon losses for the private investors.
Oncolytics Biotech 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Oncolytics Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Royal Bank and Oncolytics Biotech Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Royal Bank and Oncolytics Biotech

The main advantage of trading using opposite Royal Bank and Oncolytics Biotech positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Royal Bank position performs unexpectedly, Oncolytics Biotech can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will offset losses from the drop in Oncolytics Biotech's long position.
The idea behind Royal Bank of and Oncolytics Biotech pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Valuation
Check real value of public entities based on technical and fundamental data
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Global Correlations
Find global opportunities by holding instruments from different markets